Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Hunter Syndrome Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the Hunter Syndrome pipeline drug profiles, including Hunter Syndrome clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Hunter Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Hunter Syndrome clinical trials studies, Hunter Syndrome NDA approvals (if any), and product development activities comprising the technology, Hunter Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Hunter Syndrome Pipeline Report

• Hunter Syndrome Pipeline report offers a comprehensive analysis of 10+ companies and 10+ therapies.

• The leading Hunter Syndrome Companies includes AVROBIO, Capsida Biotherapeutics, GENERIUM Pharmaceuticals, Denali Therapeutics, REGENXBIO, ArmaGen Technologies, Homology Medicines, and others.

• Promising Hunter Syndrome Pipeline therapies includes Elaprase for intravenous (IV) infusion, Idursulfase, idursulfase-IT, Elaprase, Neurobehavioral testing, AGT-182, and others.

• The Hunter Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence Hunter Syndrome R&D. The Hunter Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Hunter Syndrome.

Explore more information on the latest breakthroughs in the Hunter Syndrome treatment landscape of the report and Hunter Syndrome Pipeline Outlook @ https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hunter Syndrome Overview
Hunter syndrome is a mucopolysaccharide disease caused by the enzymatic deficiency of iduronate-2-sulfatase (I2S). This is also called as mucopolysaccharoidosis Type II. Hunter syndrome is a hereditary disease in which the breakdown of a mucopolysaccharide (a chemical that is widely distributed in the body outside of cells) is defective. This chemical builds up and causes a characteristic facial appearance, abnormal function of multiple organs, and in severe cases, early death. In the neuronopathic form of this disorder, physical and mental development reaches a peak at 2-4 years of age with subsequent deterioration.

Recent Development Activities in the Hunter Syndrome Treatment Landscape
• JR-141 is currently in the phase III stage of development followed by TAK-609 and Hunterase in phase II clinical development and DNL310, RGX-121, SB-913 and TAK-531, AVR-RD-05 in phases I/II, I and IND clinical development.
• In October 2020, AVROBIO announced an exclusive, worldwide license agreement and a collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome, a rare and deadly lysosomal disorder that primarily affects young boys.
• Denali Therapeutics announces the publication of two new papers elaborating its blood-brain barrier delivery technology in science translational medicine in May 2020.
• The first Denali-authored paper by Kariolis et al. entitled "Brain delivery of therapeutic proteins using a novel Fc fragment blood-brain barrier transport vehicle in mice and monkeys," published in STM, explains the development and engineering of the TV platform, and displays how it rises the brain exposure and distribution of specific antibodies in preclinical models including non-human primates.

Request a sample and discover the recent advances in Hunter Syndrome Pipeline Therapies, visit Hunter Syndrome Treatment Landscape @ https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hunter Syndrome Emerging Drugs Profile

DNL310: Denali Therapeutics Inc
DNL310, or ETV:IDS, is a recombinant form of the iduronate 2-sulfatase ("IDS") enzyme engineered to cross the blood-brain barrier using Denali's proprietary ETV technology. DNL310 is intravenously administered and intended to improve overall clinical manifestations of Hunter Syndrome, including neurological symptoms, which are not adequately addressed by currently approved therapies. The FDA has granted orphan drug status and a rare pediatric disease designation to Denali Therapeutics pipeline candidate, DNL310. The drug is being evaluated in Phase I/II clinical trial to treat Hunter Syndrome.

RGX-121: Regenxbio Inc.
RGX-121 is a product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. RGX-121 is designed to use the AAV9 vector to deliver the human iduronate-2-sulfatase gene (IDS) which encodes the iduronate-2-sulfatase (I2S) enzyme to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted I2S beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 has received orphan drug product, rare pediatric disease and Fast Track designations from the U.S. Food and Drug Administration.

Hunter Syndrome Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Hunter Syndrome. The companies which have their Hunter Syndrome drug candidates in the most advanced stage, i.e. Phase I/II include, Denali Therapeutics.

Get to know more information about the Hunter Syndrome Emerging Drugs and Companies of the report @ https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hunter Syndrome Pipeline Report

• Coverage- Global

• Hunter Syndrome Companies- AVROBIO, Capsida Biotherapeutics, GENERIUM Pharmaceuticals, Denali Therapeutics, REGENXBIO, ArmaGen Technologies, Homology Medicines, and others

• Hunter Syndrome Pipeline Therapies- Elaprase for intravenous (IV) infusion, Idursulfase, idursulfase-IT, Elaprase, Neurobehavioral testing, AGT-182, and others

• Hunter Syndrome Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Hunter Syndrome Market Drivers and Hunter Syndrome Market Barriers, click here Hunter Syndrome Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Hunter Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. DNL310: Denali Therapeutics Inc
11. Drug profiles in the detailed report…..
12. Preclinical stage products
13. AVR RD 05: AVROBIO
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Hunter Syndrome Key Companies
17. Hunter Syndrome Key Products
18. Hunter Syndrome- Unmet Needs
19. Hunter Syndrome- Market Drivers and Barriers
20. Hunter Syndrome- Future Perspectives and Conclusion
21. Hunter Syndrome Analyst Views
22. Hunter Syndrome Key Companies
23. Appendix

Got Queries? Find out the related information on Hunter Syndrome Mergers and acquisitions, Hunter Syndrome Licensing Activities, and Click here for Hunter Syndrome Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trending Market Research Reports in 2023 By DelveInsight

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Oncolytic virus cancer therapy pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Persistent Corneal Epithelial Defects Market- https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

Technical Due Diligence Firms | Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market- https://www.delveinsight.com/report-store/hand-foot-syndrome-market

Ptosis Market- https://www.delveinsight.com/report-store/ptosis-market

Uncomplicated Urinary Tract Infection Market- https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market

Otitis Media Market- https://www.delveinsight.com/report-store/otitis-media-market

Pelizaeus-Merzbacher Disease Market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market

Transverse Myelitis Market- https://www.delveinsight.com/report-store/transverse-myelitis-market

PCSK9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

Cough in IPF Market- https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market

Advanced Liver Cancer Market- https://www.delveinsight.com/report-store/advanced-liver-cancer-market

Chagas Disease Market- https://www.delveinsight.com/report-store/chagas-disease-market

Familial Adenomatous Polyposis Market- https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market

Metastatic Pancreatic Cancer Market- https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-market

Trichotillomania Market- https://www.delveinsight.com/report-store/trichotillomania-ttm-market

Temporomandibular Disorders Market- https://www.delveinsight.com/report-store/temporomandibular-disorders-market

Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-neoplasm-market

Joint Reconstruction Devices Market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market

Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market

Atrial Flutter Market- https://www.delveinsight.com/report-store/atrial-flutter-market

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.